The role of afatinib in patients with EGFR NSCLC
Published: 18 Apr 2019
Views: 978
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
Dr Antonio Passaro speaks to ecancer at the European Lung Cancer Congress 2019.
He outlines the Phase III trial which evaluates the role of afatinib in patients with EGFR NSCLC.
Dr Passaro describes the data so far, and also some of the future prospects for the research, including a comparison of clinical trail and clinical practise data.
He finishes by outlining the toxicity profile of the combination.
Related Videos
Checkmate 227: Final analysis for the non small cell lung cancer trial
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
7 Oct 2019
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
30 Sep 2019
PLEIADES: Daratumumab combinations for multiple myeloma
Dr Ajai Chari - Mount Sinai, New York City, USA
25 Sep 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
18 Apr 2019
ASCO GU 2019 renal highlights
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
14 Feb 2019
Patient treatment preferences in relapsed/refractory multiple myeloma
Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos
3 Dec 2018
Landscape change with oral proteasome maintenance in multiple myeloma patients
Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lo...
3 Dec 2018
Key developments in prostate cancer
Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto an...
22 Oct 2018
